# Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC

> **NCT04779554** · PHASE2 · RECRUITING · sponsor: **Prakash Pandalai** · enrollment: 100 (estimated)

## Conditions studied

- Peritoneal Carcinomatosis

## Interventions

- **DRUG:** Mitomycin C, flat dose 40 mg
- **DRUG:** Mitomycin C, weight-based dose 12.5 mg/m2

## Key facts

- **NCT ID:** NCT04779554
- **Lead sponsor:** Prakash Pandalai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-04
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04779554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04779554, "Flat Dose vs. Weight-based IP Chemotherapy for CRS/HIPEC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04779554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*